Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12297591rdf:typepubmed:Citationlld:pubmed
pubmed-article:12297591lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12297591lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12297591lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:12297591lifeskim:mentionsumls-concept:C0026259lld:lifeskim
pubmed-article:12297591lifeskim:mentionsumls-concept:C2349943lld:lifeskim
pubmed-article:12297591pubmed:issue6lld:pubmed
pubmed-article:12297591pubmed:dateCreated2002-9-25lld:pubmed
pubmed-article:12297591pubmed:abstractTextThe authors report a patient with severe secondary progressive MS who responded to mitoxantrone but developed a fatal acute myeloblastic leukemia 15 months after completion of mitoxantrone therapy. Therapy-related acute leukemia (TRAL) in relation with mitoxantrone is rare; this patient was the first case among a cohort of 802 French MS patients treated with mitoxantrone. Nevertheless, this case stresses the need to further evaluate the long-term risk of TRAL in patients with MS who receive mitoxantrone.lld:pubmed
pubmed-article:12297591pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12297591pubmed:languageenglld:pubmed
pubmed-article:12297591pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12297591pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12297591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12297591pubmed:statusMEDLINElld:pubmed
pubmed-article:12297591pubmed:monthSeplld:pubmed
pubmed-article:12297591pubmed:issn0028-3878lld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:ClanetMMlld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:LaurentGGlld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:EdanGGlld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:Rigal-HuguetF...lld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:WaubantEElld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:RedmanC LCLlld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:BrassatDDlld:pubmed
pubmed-article:12297591pubmed:authorpubmed-author:Le PageEElld:pubmed
pubmed-article:12297591pubmed:issnTypePrintlld:pubmed
pubmed-article:12297591pubmed:day24lld:pubmed
pubmed-article:12297591pubmed:volume59lld:pubmed
pubmed-article:12297591pubmed:ownerNLMlld:pubmed
pubmed-article:12297591pubmed:authorsCompleteYlld:pubmed
pubmed-article:12297591pubmed:pagination954-5lld:pubmed
pubmed-article:12297591pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12297591pubmed:meshHeadingpubmed-meshheading:12297591...lld:pubmed
pubmed-article:12297591pubmed:meshHeadingpubmed-meshheading:12297591...lld:pubmed
pubmed-article:12297591pubmed:meshHeadingpubmed-meshheading:12297591...lld:pubmed
pubmed-article:12297591pubmed:meshHeadingpubmed-meshheading:12297591...lld:pubmed
pubmed-article:12297591pubmed:meshHeadingpubmed-meshheading:12297591...lld:pubmed
pubmed-article:12297591pubmed:meshHeadingpubmed-meshheading:12297591...lld:pubmed
pubmed-article:12297591pubmed:meshHeadingpubmed-meshheading:12297591...lld:pubmed
pubmed-article:12297591pubmed:year2002lld:pubmed
pubmed-article:12297591pubmed:articleTitleTherapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.lld:pubmed
pubmed-article:12297591pubmed:affiliationDepartment of Neurology, Hôpital Purpan, Toulouse University Medical Center, Toulouse, France. dbrassat@yahoo.frlld:pubmed
pubmed-article:12297591pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12297591pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12297591lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12297591lld:pubmed